Treatment of bronchial asthma: as an additional treatment for bronchial asthma in patients with persistent asthma of mild and moderate severity, which is insufficiently controlled by inhaled corticosteroids, as well as in the case of insufficient asthma control by short-acting β-agonists and used. In patients with asthma taking Singlon , this drug also relieves symptoms of seasonal allergic rhinitis. Prevention of asthma, the main component of which is bronchospasm caused by physical activity. Relieving symptoms of seasonal and year-round allergic rhinitis.
Composition and form of release
Main active ingredient: montelukast.
Excipients: mannitol, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, aspartame, cherry flavor, magnesium stearate, etc.
Available in the form of chewable tablets, in two dosages – 4 and 10 mg of montelukast in each.
The specified drug belongs to the group of cystenyl-leukotriene receptor blockers, which play an important role in the development of broncho-obstructive syndrome.
As a result, the drug is effective in the treatment of obstructive diseases that develop in the lower parts of the respiratory system.
Montelukast, which is the main active ingredient of the drug, has the property, when applied, to bind to cystenyl-leukotriene receptors (CysLT1 receptors), which are responsible for the occurrence of bronchospasm, sputum secretion from the bronchi, and other symptoms accompanying obstructive bronchitis.
Capable of inhibiting bronchoconstriction in patients with asthma.
It has the property of stopping the arising bronchospasm at all stages of its development, due to the ability to reduce the body’s response to allergic antigens.
The use of montelukast leads to a decrease in the number of eosinophils in the airways.
This drug is used as a drug for the additional treatment of bronchial asthma in children aged 2 to 14 years, suffering from persistent asthma, both mild and moderate, including if they are insufficiently controlled by inhaled GCS.
It is also effective if the patient has insufficient asthma control with short-acting β-agonists.
Also applicable for:
- symptomatic treatment of seasonal allergic rhinitis in patients with bronchial asthma;
- prevention of asthma, in which bronchospasm is provoked by physical exertion;
- relieve symptoms of seasonal and perennial allergic rhinitis.
You should not use the specified drug if the patient has had a previous hypersensitivity (allergy) with respect to one of the components that are part of the drug – both main and auxiliary.
In pediatrics, it is used from 2 years of age.
Application during pregnancy and lactation
Treatment of pregnant women is carried out with every possible care, only for serious indications.
Breastfeeding should be suspended during treatment.
Method of administration and dosage
The drug is used for asthma and allergic rhinitis (both seasonal and year-round), 1 tablet 1 time per day.
In the treatment of asthma – in the evening, 1-2 hours after the evening meal. For the treatment of allergic rhinitis, the time of taking the drug can be selected on an individual basis.
Children aged 2 to 5 years take the drug in a dosage of 4 mg of montelukast, children aged 6 to 14 years – in a dosage of 5 mg of montelukast.
Overdose with this drug does not cause any particular adverse events. In rare cases, the following were observed:
- drowsiness, psychomotor hyperactivity;
Symptomatic therapy is recommended.
Usually the drug is well tolerated. Side effects can occur only in rare cases. In particular, there may be observed:
- anaphylactic reactions, hypersensitivity reactions, including anaphylactic shock;
- upper respiratory tract infections;
- headache, abdominal pain, thirst, nausea, vomiting, dyspepsia;
- increased bleeding;
- sleep disturbances, nightmares, hallucinations, insomnia, irritability, anger, agitation, hostility, depression, disorientation, suicidal thoughts;
- lethargy, dizziness, paresthesia, hypersthesia, palpitations;
- hepatitis, increased levels of hepatic transaminases;
- arthralgia, myalgia, including muscle cramps;
- asthenia / fatigue, discomfort, swelling, fever;
- nose bleed.
Storage conditions and periods
This medicinal product is able to retain its medicinal properties for 2 years from the date of manufacture indicated on the package.
The drug should be kept out of the reach of children. Storage temperature should not exceed 25 ° C.